AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

   Clear Filter

Jul 26, 2013

AbbVie Reports Second-Quarter 2013 Financial Results

NORTH CHICAGO, Ill., July 26, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced financial results for the second quarter ended June 30, 2013.

Jul 08, 2013

Stacy London Launches Uncover Your Confidence™ Campaign to Empower People Living with Psoriasis

NORTH CHICAGO, Ill., July 8, 2013 /PRNewswire/ -- Stacy London, style expert and co-host of TLC's "What Not to Wear," today announced her partnership with AbbVie (NYSE: ABBV) on a new psoriasis campaign called Uncover Your Confidence. The campaign features educational resources and style advice for the estimated 7.5 million American men and women living with psoriasis.[1] Commonly mistaken as "just a skin condition," psoriasis is actually a chronic disease of the immune system that appears on the skin.

Jun 17, 2013

AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting

NORTH CHICAGO, Ill., June 17, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced preliminary results from a Phase I study of ABT-199/GDC-0199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, in patients with high-risk relapsed/refractory chronic lymphocytic leukemia (CLL), and in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL). High-risk CLL patients are those with deletions of chromosome 17p or whose disease is refractory to fludarabine therapy. These data were presented at the 18th Congress of the European Hematology Association (EHA) in Stockholm, Sweden.

Jun 13, 2013

AbbVie Presents First Study Assessing the Role of Predefined Doses of Methotrexate When Used in Combination with HUMIRA® (adalimumab) for Rheumatoid Arthritis

MADRID, June 13, 2013 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced the results from the CONCERTO trial, the first randomized, controlled trial assessing different predefined doses of methotrexate (MTX) in combination with HUMIRA® (adalimumab) for the treatment of moderate to severe rheumatoid arthritis (RA). CONCERTO shows that at week 26 of treatment, a statistically significant increasing trend was observed in the proportion of patients achieving low disease activity with an increasing dose of MTX when used with open-label HUMIRA®. Results were presented at the European League Against Rheumatism (EULAR) 2013 Congress in Madrid, Spain.

Jun 05, 2013

AbbVie to Participate in 34th Annual Goldman Sachs Global Healthcare Conference

NORTH CHICAGO, Ill., June 5, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 34th Annual Goldman Sachs Global Healthcare Conference on Thursday, June 13, 2013.  Bill Chase, executive vice president and chief financial officer, and Scott Brun, M.D., vice president, pharmaceutical development, will take part in a question and answer session at 12:40 p.m. Central time.

Jun 03, 2013

AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting

NORTH CHICAGO, Ill., June 3, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from a Phase I study of ABT-199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL), the most common leukemia in the United States, and relapsed/refractory non-Hodgkin's lymphoma (NHL).  Results from the study were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO).

May 30, 2013

AbbVie Announces Market Availability of New CREON® (pancrelipase) 36,000 Lipase-unit Capsules for Patients with Exocrine Pancreatic Insufficiency

NORTH CHICAGO, Ill., May 30, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that a new, higher-dose capsule of CREON® (pancrelipase) Delayed-Release Capsules is commercially available in the United States.  The U.S. Food and Drug Administration (FDA) recently approved CREON in a 36,000 lipase-unit dose to treat patients with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis, swelling of the pancreas that lasts a long time (chronic pancreatitis), removal of some or all of the pancreas (pancreatectomy), or other conditions.  This new strength is the highest dose of pancreatic enzyme replacement therapy (PERT) currently available and approved by the FDA.

May 28, 2013

AbbVie to Participate in 2013 Jeffries Global Healthcare Conference

NORTH CHICAGO, Ill., May 28, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 2013 Jeffries Global Healthcare Conference on Tuesday, June 4, 2013.  Bill Chase, executive vice president and chief financial officer, and Scott Brun, M.D., vice president, pharmaceutical development, will take part in a question and answer session at 8:00 a.m. Central time.

May 20, 2013

AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy

NORTH CHICAGO, Ill., May 20, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease (CKD) and type 2 diabetes.  SONAR is a large, multinational, double-blind, placebo-controlled clinical study that is expected to enroll more than 4,000 patients with diabetic nephropathy.  The study will evaluate atrasentan's impact on renal outcomes, such as the onset of end-stage renal disease (ESRD), as defined by need for chronic dialysis, transplant or death due to renal failure progression.i

May 17, 2013

AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease

NORTH CHICAGO, Ill. and MECHELEN, Belgium, May 17, 2013 /PRNewswire/ -- Galapagos NV (Euronext: GLPG) and AbbVie (NYSE: ABBV) announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease.  Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3.  Upon successful completion of the study, expected in Q2 2015, AbbVie will pay Galapagos $50 million.  The terms of the collaboration extension are in addition to previously agreed upon financial terms.  AbbVie will be responsible for funding and performing clinical development beyond Phase 2, and completing regulatory and commercialization activities.